Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT01719380
Title	Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Recruitment	Completed
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	colorectal cancer
Therapies	Cetuximab + Encorafenib Alpelisib + Cetuximab + Encorafenib
Age Groups:	adult
Covered Countries	USA \| NOR \| NLD \| ITA \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS